CN1897975B - 口服给药的水溶性药物纳米颗粒组合物及其制备方法 - Google Patents

口服给药的水溶性药物纳米颗粒组合物及其制备方法 Download PDF

Info

Publication number
CN1897975B
CN1897975B CN2004800386637A CN200480038663A CN1897975B CN 1897975 B CN1897975 B CN 1897975B CN 2004800386637 A CN2004800386637 A CN 2004800386637A CN 200480038663 A CN200480038663 A CN 200480038663A CN 1897975 B CN1897975 B CN 1897975B
Authority
CN
China
Prior art keywords
composition
water
sodium
soluble drug
insulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2004800386637A
Other languages
English (en)
Chinese (zh)
Other versions
CN1897975A (zh
Inventor
裵哲民
闵美泓
黄俊硕
赵庆美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Samyang Biopharmaceuticals Corp
Original Assignee
Samyang Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samyang Corp filed Critical Samyang Corp
Publication of CN1897975A publication Critical patent/CN1897975A/zh
Application granted granted Critical
Publication of CN1897975B publication Critical patent/CN1897975B/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1816—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/31—Somatostatins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN2004800386637A 2003-12-24 2004-12-24 口服给药的水溶性药物纳米颗粒组合物及其制备方法 Expired - Fee Related CN1897975B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR1020030096641A KR100638041B1 (ko) 2003-12-24 2003-12-24 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
KR1020030096641 2003-12-24
KR10-2003-0096641 2003-12-24
PCT/KR2004/003448 WO2005061004A1 (en) 2003-12-24 2004-12-24 Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof

Publications (2)

Publication Number Publication Date
CN1897975A CN1897975A (zh) 2007-01-17
CN1897975B true CN1897975B (zh) 2010-12-01

Family

ID=36763862

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2004800386637A Expired - Fee Related CN1897975B (zh) 2003-12-24 2004-12-24 口服给药的水溶性药物纳米颗粒组合物及其制备方法

Country Status (9)

Country Link
US (1) US7674767B2 (cg-RX-API-DMAC10.html)
EP (1) EP1696961A4 (cg-RX-API-DMAC10.html)
JP (1) JP4814107B2 (cg-RX-API-DMAC10.html)
KR (1) KR100638041B1 (cg-RX-API-DMAC10.html)
CN (1) CN1897975B (cg-RX-API-DMAC10.html)
AU (1) AU2004305395B2 (cg-RX-API-DMAC10.html)
CA (1) CA2549383C (cg-RX-API-DMAC10.html)
NZ (1) NZ548086A (cg-RX-API-DMAC10.html)
WO (1) WO2005061004A1 (cg-RX-API-DMAC10.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
ES2372499T3 (es) 2004-05-19 2012-01-20 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Uso de un detergente para la eliminación no quirúrgica de grasa.
US20070021325A1 (en) * 2005-07-21 2007-01-25 Mediplex Corporation Drug formulation containing a solubilizer for enhancing solubility, absorption, and permeability
KR100792557B1 (ko) * 2006-04-05 2008-01-09 한남대학교 산학협력단 나노 캡슐화를 이용하여 제조된 지질 핵 및 고분자 쉘구조를 갖는 단백질 약물 전달용 나노 미립구
WO2008067573A2 (en) * 2006-12-01 2008-06-05 Tshwane University Of Technology Drug delivery system
EP2170283B1 (en) 2007-06-22 2019-01-09 Board of Regents, The University of Texas System Formation of stable submicron peptide or protein particles by thin film freezing
HRP20191104T1 (hr) * 2007-09-25 2019-09-20 Solubest Ltd. Pripravci koji sadrže lipofilne aktivne spojeve i postupak za njihovu pripremu
US8802156B2 (en) 2007-11-14 2014-08-12 Laboratorios Farmacéuticos Rovi, S.A. Pharmaceutical forms for the release of active compounds
FR2925333B1 (fr) * 2007-12-19 2012-04-13 Farid Bennis Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
US20100292141A1 (en) * 2007-12-28 2010-11-18 Shanghai Institute Of Pharmaceutical Industry Insulin nasal powder inhalation
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US9027633B2 (en) * 2008-03-24 2015-05-12 Auburn University Nanoparticle-enhanced phase change materials (NEPCM) with improved thermal energy storage
US20110165259A1 (en) * 2008-09-19 2011-07-07 Activus Pharma Co., Ltd. Composite organic compound powder for medical use, method for producing same and suspension of same
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
EP2266546A1 (en) * 2009-06-08 2010-12-29 Advancell Advanced in Vitro Cell Technologies,S.A. Process for the preparation of colloidal systems for the delivery of active compounds
IN2012DN00311A (cg-RX-API-DMAC10.html) 2009-07-09 2015-05-08 Oshadi Drug Administration Ltd
WO2011017297A2 (en) 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
US20120237492A1 (en) 2011-02-18 2012-09-20 Kythera Biopharmaceuticals, Inc. Treatment of submental fat
CA2829629A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
EP2739303B1 (en) * 2011-08-07 2020-04-01 Transgene Biotek Ltd. A novel method for peroral delivery of insulin and its analogues for therapeutic usage
WO2013049749A2 (en) 2011-09-29 2013-04-04 Plx Pharma Inc. pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME
CN102552292A (zh) * 2011-12-29 2012-07-11 石药集团欧意药业有限公司 一种阿仑膦酸钠维生素d3药物制剂
CA2874490C (en) 2012-05-23 2021-11-16 The Ohio State University Tertiary quaternary amine-based cationic lipid nanoparticle compositions and methods of making and methods of using the same
KR101501924B1 (ko) * 2012-07-30 2015-03-18 가톨릭관동대학교산학협력단 담즙산염과 모노올레인 분산액을 포함하는 결정체, 이의 제조방법, 이를 이용한 단백질 분리 및 전달체로서의 용도
JP6538025B2 (ja) 2013-03-15 2019-07-03 リズム・ファーマシューティカルズ・インコーポレイテッド 医薬組成物
CN103638527A (zh) * 2013-12-05 2014-03-19 浙江大学 促红细胞生成素载药纳米粒及其应用
EP3151856B1 (en) * 2014-06-06 2019-08-07 Merck Patent GmbH Antigen-loaded chitosan nanoparticles for immunotherapy
WO2016004067A1 (en) * 2014-06-30 2016-01-07 Stealth Biotherapeutics Corp Aromatic-cationic peptide formulations, compositions and methods of use
WO2016046845A1 (en) 2014-09-25 2016-03-31 Manu Chaudhary Stealth, targeted nanoparticles (stn) for oral drug delivery
US11246934B2 (en) * 2015-01-05 2022-02-15 B.G. Negev Technologies & Applications Ltd. At Ben-Gurion University Nanoparticles and methods for preparation thereof
CA3014406A1 (en) 2016-02-16 2017-08-24 Strongbridge Biopharma plc Veldoreotide with poor solubitliy in physiological conditions for use in the treatment of acromegaly, acromegaly cancer, sst-r5 expressing tumors, type 2 diabetes, hyperglycemia,and hormone-related tumors
US10213448B2 (en) 2016-03-25 2019-02-26 Novazoi Theranostics Ethanolamine-based lipid biosynthetic compounds, method of making and use thereof
US11491114B2 (en) 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
US20180271792A1 (en) * 2017-03-23 2018-09-27 Rezolute, Inc. Oral delivery of physiologically active substances
EP3655009B1 (en) 2017-07-20 2023-10-11 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nanoparticle compositions
EP3706722B1 (en) * 2017-11-10 2024-04-24 President And Fellows Of Harvard College Methods for reducing bioavailability and absorption of ingested substances
US11793758B2 (en) * 2018-06-22 2023-10-24 Bioralix B.V. Formulations of biological polymers for oral administration
CN110720641A (zh) * 2019-10-18 2020-01-24 广东海洋大学 一种具有减脂增肌功效的蛋白冻干块及其制备方法
KR20220158031A (ko) 2020-03-26 2022-11-29 피엘엑스 옵코 인코포레이티드 pH 의존성 재구성이 가능한 제약 담체 및 그의 제조 및 사용 방법
EP4178530A1 (en) * 2020-07-09 2023-05-17 F. Hoffmann-La Roche AG Concentrated compositions of proteins, their preparation and use thereof
US12426594B2 (en) 2020-09-24 2025-09-30 Everest Medical Innovation GmbH Cryoprotective compositions and methods for protection of a surgical site during cryosurgery
US12453805B2 (en) 2020-09-24 2025-10-28 Everest Medical Innovation GmbH Cryoprotective compositions, surgical kits, and methods for protection of a surgical site during cryosurgery
CN113384705A (zh) * 2021-06-28 2021-09-14 西南大学 泊洛沙姆修饰的脂质体的制备及在口服药物递送中的应用
US20250025535A1 (en) * 2021-11-19 2025-01-23 Nanoform Finland Oyj A composition comprising nanosized active pharmaceutical ingredient
CN114366717B (zh) * 2022-01-11 2023-06-09 四川农业大学 一种基于egcg纳米粒的肠溶固体分散体颗粒、制备方法及其应用
CN118662475B (zh) * 2023-03-16 2026-02-06 清华大学 固体化自微乳疫苗的制备与应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
EP0771566A1 (en) * 1995-05-26 1997-05-07 Universidade De Santiago De Compostela Stabilization of colloidal systems by the formation of ionic lipid-polysaccharide complexes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6289617A (ja) * 1985-08-12 1987-04-24 ウイリアム　ガウフ　タツカ− 薬剤組成物およびその調製方法
US6191105B1 (en) 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1997004747A1 (en) * 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US6120751A (en) * 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
JPH11130658A (ja) * 1997-10-30 1999-05-18 Teijin Ltd 水性懸濁医薬品組成物
JP2000024487A (ja) * 1998-07-10 2000-01-25 Nisshin Oil Mills Ltd:The 油性組成物を含有した乳化組成物
CA2352389C (en) * 1998-11-27 2009-01-20 Kanji Takada An oral formulation for gastrointestinal drug delivery
DE19940794A1 (de) * 1999-08-27 2001-03-01 Lohmann Therapie Syst Lts Pharmazeutische Zubereitung
KR20020013174A (ko) * 2000-08-11 2002-02-20 민경윤 경구 흡수율이 낮은 약물의 흡수율을 증가시키기 위한경구용 조성물
AU2002254205B2 (en) * 2001-03-15 2007-05-10 Enteron Pharmaceuticals, Inc. Method of treating inflammatory disorders of the gastrointestinal tract using topical active corticosteroids
PT1429731E (pt) * 2001-09-19 2007-04-30 Elan Pharma Int Ltd Formulações de insulina nanoparticulada
US20030134810A1 (en) * 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
JP4882200B2 (ja) * 2001-11-13 2012-02-22 アステラス製薬株式会社 水溶性薬物徐放化技術
US20040062778A1 (en) * 2002-09-26 2004-04-01 Adi Shefer Surface dissolution and/or bulk erosion controlled release compositions and devices
JP2007509981A (ja) * 2003-10-31 2007-04-19 テバ ファーマシューティカル インダストリーズ リミティド 薬物デリバリー用ナノ粒子

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
EP0771566A1 (en) * 1995-05-26 1997-05-07 Universidade De Santiago De Compostela Stabilization of colloidal systems by the formation of ionic lipid-polysaccharide complexes

Also Published As

Publication number Publication date
AU2004305395A1 (en) 2005-07-07
US20070154559A1 (en) 2007-07-05
EP1696961A4 (en) 2010-09-01
CA2549383C (en) 2010-08-31
NZ548086A (en) 2008-03-28
WO2005061004A1 (en) 2005-07-07
JP2007517023A (ja) 2007-06-28
HK1096295A1 (en) 2007-06-01
KR100638041B1 (ko) 2006-10-23
EP1696961A1 (en) 2006-09-06
US7674767B2 (en) 2010-03-09
KR20050065014A (ko) 2005-06-29
JP4814107B2 (ja) 2011-11-16
CN1897975A (zh) 2007-01-17
CA2549383A1 (en) 2005-07-07
AU2004305395B2 (en) 2008-05-22

Similar Documents

Publication Publication Date Title
JP4814107B2 (ja) 水溶性薬物を含有する経口投与用ナノ粒子組成物及びその製造方法
Alai et al. Application of polymeric nanoparticles and micelles in insulin oral delivery
Shalaby et al. Bioadhesive chitosan-coated cationic nanoliposomes with improved insulin encapsulation and prolonged oral hypoglycemic effect in diabetic mice
US9839617B2 (en) Nanoencapsulation of hydrophilic active compounds
JP2007517023A5 (cg-RX-API-DMAC10.html)
CN102908627B (zh) 用于口服胰岛素递送的pH敏感性纳米粒子
US9101547B2 (en) Enteric-coated capsule containing cationic nanoparticles for oral insulin delivery
Salvioni et al. Oral delivery of insulin via polyethylene imine-based nanoparticles for colonic release allows glycemic control in diabetic rats
EP1357902A2 (en) Therapeutic agents complexed with calcium phosphate and encased by casein
US7087246B2 (en) Controlled release preparation of insulin and its method
CN110662550A (zh) 生理活性物质的口服给药
Boushra et al. Development of bi-polymer lipid hybrid nanocarrier (BLN) to improve the entrapment and stability of insulin for efficient oral delivery
US20140120162A1 (en) Bioadhesive Drug Delivery Compositions
CN102293748B (zh) 一种口服聚乙二醇化胰岛素pH敏感纳米粒及其制备方法
US20080241260A1 (en) Compositions for Enhanced Absorption of Biologically Active Agents
CN118662476A (zh) 一种含特立帕肽纳米粒的口服制剂及其制备方法
HK1096295B (en) Nanoparticle compositions of water-soluble drugs for oral administration and preparation methods thereof
WO2017134655A1 (en) Improved oral absorption of octreotide and salts thereof
WO2006072613A2 (fr) Préparation contenant des microparticules d'une résine polysaccharidique insoluble portant un principe actif biopolymérique, ainsi que son procédé de fabrication
Dorly et al. Oral Delivery of Insulin via Polyethylene Imine-based

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1096295

Country of ref document: HK

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1096295

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: SAMYANG BIOPHARMACEUTICALS CORPORATION

Free format text: FORMER OWNER: SAM YANG CO., LTD.

Effective date: 20120406

C41 Transfer of patent application or patent right or utility model
TR01 Transfer of patent right

Effective date of registration: 20120406

Address after: Seoul, South Korea

Patentee after: SAMYANG BIOPHARMACEUTICALS Corp.

Address before: Seoul, South Kerean

Patentee before: SAMYANG Corp.

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20101201

Termination date: 20211224

CF01 Termination of patent right due to non-payment of annual fee